aprea

Aprea is a proper noun with multiple uses. In onomastics, it is an Italian surname found among individuals of Italian heritage and in communities with Italian ancestry. The name appears in various professional fields and regions, reflecting its cultural origin.

Aprea Therapeutics, Inc. is a biotechnology company that has developed APR-246, also known as eprenetapopt, a small molecule designed to reactivate mutant p53 tumor suppressor protein. The program targets cancers driven by TP53 mutations, a genetic alteration common in several malignancies. APR-246 has been studied primarily in combination with other therapies, such as azacitidine, in patients with TP53-mutant myelodysplastic syndromes and acute myeloid leukemia. The company situates its work within the broader field of p53 pathway therapeutics, aiming to restore normal p53 function as a means to inhibit cancer cell growth.

Beyond this, the term Aprea may be encountered in other, less common contexts, typically as a surname or as part of branding for entities seeking a distinctive identity. As with many proper nouns, usage and recognition can vary by region and over time.